<?xml version="1.0" encoding="UTF-8"?>
<p>In a study of the MERS-CoV syndrome, IL-6, IL-8 and IL-1β were significantly elevated and, similar to the picture in CoVID-19, there was a delayed phasic cytokine response with the development of hypoxaemia and ARDS.(
 <xref rid="R31" ref-type="bibr">31</xref>–
 <xref rid="R33" ref-type="bibr">33</xref>) A small study (21 patients) from China looked at a single dose of 400 mg (1 patient received a second dose) in 21 patients. All were confirmed cases and had markedly elevated IL-6. All patients improved over the next few days with an initial resolution of fever, improvement in gas exchange, normalization of the CRP by Day 5 and clearing of pulmonary infiltrates.(
 <xref rid="R34" ref-type="bibr">34</xref>) No short-term adverse events were reported. All of the patients had deteriorated despite routine therapies in the previous week, and the agent is now listed as a treatment option for severe or critical cases with elevated IL-6 in the National Health Commission of the People's Republic of China COVID-19 Diagnosis and Treatment Guide.(
 <xref rid="R35" ref-type="bibr">35</xref>) A very recent case study has described the successful use of Tmab in a patient on maintenance therapy for multiple myeloma who had received bortezomib, thalidomide and dexamethasone therapy approximately 4 years previously and had been on thalidomide maintenance since then. He presented with a shortness of breath only but responded rapidly to Tmab after having deteriorated despite the oral antiviral therapy, umifenovir 200 mg/8 h.(
 <xref rid="R36" ref-type="bibr">36</xref>)
</p>
